Yahong Pharmaceutical announced that APL-1702 was approved for marketing in China in March 2026 to treat patients aged 18 and above with histologically confirmed grade 2 cervical intraepithelial neoplasia. The company recently revealed that APL-1702 was selected for the 38th Annual Meeting of the International Papillomavirus Society in 2026, which will be published in the form of electronic posters and posters for two clinical research data on CIN2. The phased results of the AEGIS study showed that as of September 16, 2026, the histological downturn rate for week 24 and week 36 was 81.6% and 91.5%, respectively; in APRICITY's post-factual exploratory analysis, the histological decline rate for patients under 30 years old and not infected with HPV16/18 was 80%.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.